Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BA3021
CAB-ROR2-ADC · 1 trial · 4 indications
Assess dose limiting toxicity as defined in the protocol
Frequency and severity of AEs and/or SAEs
Proportion of patients who achieve a confirmed CR or PR
| Arm | Type | Description |
|---|---|---|
| Monotherapy - CAB-ROR2-ADC (BA3021) alone | EXPERIMENTAL | BA3021 alone Q2W dosing regimen |
| Combination Therapy | EXPERIMENTAL | CAB-ROR2-ADC (BA3021) with PD-1 inhibitor |
| Name | Type | Description |
|---|---|---|
| CAB-ROR2-ADC | BIOLOGICAL | Conditionally active biologic anti-ROR2 antibody drug conjugate |
| PD-1 inhibitor | BIOLOGICAL | PD-1 inhibitor |
Inclusion Criteria: * Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse stan...
Top 20 of 90 competitors
CAB-ROR2-ADC is an investigational antibody-drug conjugate being studied in oncology, including non small cell lung cancer. It has also been evaluated in triple negative breast cancer, melanoma, and head and neck cancer. It is not approved and remains in clinical development.
CAB-ROR2-ADC is being developed by BioAtla, Inc., which trades under the ticker BCAB. BioAtla is the sponsor of the clinical program evaluating this antibody-drug conjugate across multiple solid tumor types.
CAB-ROR2-ADC is in Phase 1 clinical development. The Phase 1 portion of its study enrolled patients with triple negative breast cancer and head and neck cancer, with a Phase 2 portion planned for non small cell lung cancer and melanoma.
CAB-ROR2-ADC has been studied in one clinical trial, NCT03504488, titled a safety and efficacy study in patients with TNBC or head and neck cancer (Phase 1) and NSCLC or melanoma (Phase 2). The trial enrolled 132 patients across the United States, Greece, Hong Kong, Poland, Spain, and Taiwan.
No. CAB-ROR2-ADC is investigational and has not been approved by the FDA. It remains in clinical development, with its Phase 1 trial completed and no active trials currently listed.